@article{d127ee84e3994e76b7bc51b96178d486,
title = "Regulation and role of CAMKK2 in prostate cancer",
abstract = "In 2011, CAMKK2, the gene encoding calcium/calmodulin-dependent kinase kinase 2 (CAMKK2), was demonstrated to be a direct target of the androgen receptor and a driver of prostate cancer progression. Results from multiple independent studies have confirmed these findings and demonstrated the potential role of CAMKK2 as a clinical biomarker and therapeutic target in advanced prostate cancer using a variety of preclinical models. Drug development efforts targeting CAMKK2 have begun accordingly. CAMKK2 regulation can vary across disease stages, which might have important implications in the use of CAMKK2 as a biomarker. Moreover, new non-cell-autonomous roles for CAMKK2 that could affect tumorigenesis, metastasis and possible comorbidities linked to disease and treatment have emerged and could present novel treatment opportunities for prostate cancer.",
keywords = "Calcium-Calmodulin-Dependent Protein Kinase Kinase/genetics, Cell Line, Tumor, Cell Transformation, Neoplastic, Humans, Male, Prostate/pathology, Prostatic Neoplasms/genetics",
author = "Pulliam, {Thomas L.} and Pavithr Goli and Dominik Awad and Chenchu Lin and Wilkenfeld, {Sandi R.} and Frigo, {Daniel E.}",
note = "Funding Information: The authors thank K. Kage (UT MD Anderson Cancer Center) for assistance with the figures and members of the laboratory of D.E.F. for comments and edits regarding this manuscript. This work was supported by grants from the National Institutes of Health (NIH R01CA184208 and P50CA140388 (D.E.F.)), American Cancer Society (RSG-16-084-01-TBE) (D.E.F.), and an Institutional Research Grant (D.E.F.). This work was also supported by an American Legion Auxiliary Fellowship (D.A.), an Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship and Robert Hazelwood Graduate Fellowship for Cancer Research (C.L.). Funding Information: D.E.F. has received research funding from GTx, Inc., and has a familial relationship with Hummingbird Bioscience, Maia Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals and Barricade Therapeutics. The other authors declare no competing interests. The funders had no role in the conceptualization or writing of the manuscript, or in the decision to publish this article. Publisher Copyright: {\textcopyright} 2022, Springer Nature Limited.",
year = "2022",
month = jun,
doi = "10.1038/s41585-022-00588-z",
language = "English (US)",
volume = "19",
pages = "367--380",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "6",
}